Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

When It Comes To Biosimilar Marketing, Two Roads Diverge

Executive Summary

Amgen believes manufacturing nuances will set biosimilars apart and pave the way for Amgen to become a leader in the field. Others say it is a risky move to play up differences in the burgeoning market because of physician and patient concerns about the safety of biosimilars.

You may also be interested in...



Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.

Defender Or Opponent? Amgen Straddles The Biosimilar Line

Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel